Pronzato P, Landucci M, Vaira F, Vigani A, Bertelli G
Unità Operativa di Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.
Am J Clin Oncol. 1995 Jun;18(3):223-5. doi: 10.1097/00000421-199506000-00008.
Twenty outpatients with locally advanced (inoperable) or metastatic transitional cell carcinomas of the bladder were treated with carboplatin (300 mg/m2 i.v., day 1) + methotrexate (40 mg/m2 days 1 and 8) + vinblastine (6 mg/m2 days 1 and 8) (CaMV), every 4 weeks. One patient died of disease progression before completing at least 2 cycles of chemotherapy. Seven patients (35%) obtained a partial response; 8 had disease stabilization (40%) and 4 progressed (20%). Median duration of response was 3 months (range: 3-9), and median overall survival was 12+ months (range: 1-18+). None of the patients suffered grade IV toxicities, and no nephro-, neuro-, or ototoxicity was observed.
二十名患有局部晚期（无法手术）或转移性膀胱移行细胞癌的门诊患者接受了卡铂（300mg/m²静脉注射，第1天）+甲氨蝶呤（40mg/m²第1天和第8天）+长春碱（6mg/m²第1天和第8天）（CaMV）治疗，每4周进行一次。一名患者在完成至少2个周期化疗前死于疾病进展。7名患者（35%）获得部分缓解；8名病情稳定（40%），4名病情进展（20%）。中位缓解持续时间为3个月（范围：3 - 9个月），中位总生存期为12 +个月（范围：1 - 18 +个月）。没有患者出现IV级毒性反应，也未观察到肾毒性、神经毒性或耳毒性。
